First quarter, January 1 – March 31, 2026 
Net sales amounted to 0 (0). 
Other operating income amounted to 1,201 (1,662) thousand SEK. 
Operating profit (EBIT) amounted to -10,389 (10,937) thousand SEK. 
Profit after tax amounted to -10,389 (-10,937) thousand SEK. 
Earnings per share before and after dilution: -0.86 (-1.55) SEK. 
Cash flow from operating activities was -12,640 (-9,176) thousand SEK. 

Significant events during the quarter 

• Scale-up of cartridge manufacturing at FlexMedical Solutions. 
• Strong interest in the Psyros POC system at the international WHX Labs congress. 
• Positive results reported for traumatic brain injury (TBI) biomarkers in collaboration with BRAINBox Solutions, confirming broad platform potential. 

Significant events after the end of the period 

• Selected as semi-finalist in the ADLM 2026 Disruptive Technology Award Competition. 
• Secures second patent in Japan for the Psyros technology. 
• Design freeze achieved for the Psyros instrument.

CEO statement 
The first quarter of 2026 was characterized by continued focus on advancing the Psyros platform into the final stage ahead of clinical validation and commercialization. During the period, efforts were concentrated on finalizing the instrument and ensuring that the system meets the requirements for scalable manufacturing and use in clinical settings. 

Following the end of the quarter, we achieved a key milestone with the formal design freeze of the instrument. This marks a major and decisive step toward industrialization of the platform and enables pilot production of instruments to be used for verification, validation, and the regulatory clinical performance study. The final development work leading up to the completed instrument design has resulted in improved robustness and manufacturability. 

Following the end of the quarter, we received approximately SEK 11 million in R&D tax return from the UK tax authorities (HMRC). This is a significant amount that strengthens our cash position. 

Market interest in the Psyros platform remained strong during the beginning of 2026. In discussions with potential industrial partners and clinical users, as well as at international congresses such as WHX Labs in Dubai in February, the system was met with very strong and clear interest, particularly regarding the combination of ultra-sensitive analytical performance, rapid turnaround times, and unique opportunities for cost-efficient manufacturing of disposable cartridges. 

These interactions with end users and customers confirm that the Psyros system meets the market’s demanding commercial requirements, while also demonstrating strong demand for the platform across several prioritized clinical application areas. A clear example is the collaboration with the U.S.-based company BRAINBox Solutions, which has demonstrated how rapidly new biomarkers can be integrated onto the Psyros platform. We are now entering the next phase, which is fully funded by BRAINBox, where 260 clinical samples from their pivotal HeadSMART II study will be analyzed. The results will provide important data for the continued evaluation of the collaboration and the platform’s potential. 

A further external validation of the potential of the proprietary Psyros technology is that Prolight was recently selected as a semifinalist in the Disruptive Technology Award Competition 2026, organized by the international Association for Diagnostics & Laboratory Medicine congress in the United States. 

In parallel, work on the Psyros patent portfolio has continued. Following the end of the quarter, we received an additional positive patent notification in the strategically important Japanese market. This second patent application expands the scope of protection for Psyros’ core technology and is particularly relevant for rapid tests based on swab samples, for example in infectious diseases such as influenza, RSV, or COVID-19. 

Overall, we have received highly positive feedback from many international companies within the industry, as well as from end users who see Psyros as a potential next-generation point-of-care platform. We are frequently told how remarkably fast our small and cost-efficient organization has succeeded in advancing this complex and technically demanding product development program, where many large global companies have failed. 

Our upcoming milestones include validating the manufacturing process for the cartridges, initiating pilot production of instruments corresponding to the final commercial product, verifying the POC system, and commencing the final clinical performance study in Europe and the UK. 

Finally, I would like to thank our employees, partners, and shareholders for your continued support. 

Lund May 26, 2026 

Ulf Bladin 
CEO Prolight Diagnostics (publ)